Arcutis Biotherapeutics director Welgus sells $127,325 in stock

Arcutis Biotherapeutics (NASDAQ:ARQT) director Howard G. Welgus sold 4,728 shares of the company's stock on October 15, 2026, for a total of $127,325, as per a pre-arranged 10b5-1 trading plan. The stock has since risen by over 22% in a week, trading at $31.89, nearing its 52-week high of $33.01. Following the sale, Welgus acquired 4,094 shares through exercised stock options, totaling $32,458, bringing his beneficial ownership to 35,207 shares.

The company reported a significant increase in second-quarter 2026 revenue, reaching $129.9 million, surpassing forecasts and moving into profitability. Analysts have responded positively, with Guggenheim raising its price target from $35 to $38 and Jefferies maintaining a Buy rating.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.